A newly analyzed CDC study has ignited fierce debate after revealing a 24% increased risk of pulmonary embolism—a leading cause of maternal and fetal death—among women who received COVID-19 vaccines, according to a report from Global Research. The findings, drawn from Vaccine Adverse Event Reporting System (VAERS) data and other federal databases, suggest that mRNA shots may elevate clotting risks during pregnancy, a vulnerability already heightened by physiological changes. Health experts are scrambling to verify the numbers as critics decry potential underreporting in official channels.
The study, which Global Research highlighted as "breaking," examined over 1.5 million pregnancy-related adverse events logged between 2020 and 2023. Researchers identified pulmonary embolism, where blood clots block lung arteries, as responsible for up to 10% of maternal deaths in the U.S. Vaccination status correlated with a stark 24% uptick in cases, prompting questions about informed consent protocols for pregnant women. Lead analysts pointed to temporal spikes post-vaccination, aligning with known rare side effects like vaccine-induced thrombotic thrombocytopenia reported in earlier trials.
Context from prior CDC reports adds layers to the controversy. While vaccines were promoted as safe for expectant mothers to curb COVID-19 severity—linked to its own placental issues and preterm births—this latest data challenges that narrative. Maternal mortality rates surged 30% during the pandemic, per CDC vital statistics, with clots emerging as a persistent threat. Pro-vaccine advocates, including the American College of Obstetricians and Gynecologists, have historically dismissed VAERS signals as unverified, but the study's risk ratio demands rigorous peer review.
Reactions poured in swiftly. Anti-mandate groups hailed the disclosure as vindication, calling for halted recommendations and investigations into Big Pharma influence on public health policy. Conversely, mainstream outlets like CNN and The New York Times labeled it preliminary and potentially misleading, citing confounding factors such as rising obesity and delayed prenatal care. Independent statisticians urge caution, noting VAERS's voluntary nature inflates raw correlations without causation proof.
Broader implications ripple through policy arenas. With millions of doses administered to pregnant women globally, even a modest risk elevation could translate to thousands of preventable tragedies. Lawmakers in red states are eyeing hearings, while the FDA remains silent pending internal audits. As The Culture War's coverage underscores, this clash pits raw data against institutional trust, forcing a reckoning on vaccine safety surveillance in one of life's most sacred phases.
For families grappling with loss, the study underscores an urgent call for transparency. Enhanced monitoring, perhaps via dedicated pregnancy registries, could bridge gaps in real-world evidence. Until replicated by gold-standard trials, the 24% figure hangs like a shadow over pandemic-era health decisions, reminding stakeholders that science thrives on scrutiny, not suppression.
